Rheumatoid arthritis. The two faces of Rsk2 in hyperplastic disease.
Falconer J., Buckley CD.
Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?